TABLE 173Mixed treatment comparison – SIB at 12 weeks (mean change from baseline; OC populations): results

TechnologyVs placeboProbability most effective
Effect95% CIProbability more effective than placebo
Placebo–––0.000
Donepezil3.8840.343 to 7.4140.9830.506
Galantamine––––
Rivastigmine––––
Memantine3.8491.416 to 6.5090.9980.494

From: Appendix 9, Mixed-treatment comparisons performed in specified measurement populations

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.